ARCHIVES

BMS, ImClone To Develop New Drug IMC-C225, Targets EGF Receptor.

This article is from The Cancer Letter archive.

Vol. 27 No. 35 | September 28, 2001

Download PDF Visit The Full Archive

Related Articles

Yates Identifies “Probable”, “Potential” Core Grant Applicants

January 16, 1987

J&J, Amgen Settle Lawsuit Over ESAs As FDA Prepares Another Label Change.

July 18, 2008

Report calls for stronger peer review, prioritization for cancer clinical trials.

June 10, 2005

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

January 31, 2014

NCI Advisory Group, Other Cancer Meetings

August 26, 1977

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012